Bio-printing filaments (medical)

01Overview and value chain

Markers: [EC: US FDA medical device / bioresorbable implant clearance pathway | EU MDR & REACH chemical registration for bioresorbable polymer medical devices | China NMPA medical device approval | OECD: Bio-based materials | Regulator: FDA (USA), REACH (EU), NMPA (CN)]

Bio-printing filaments (medical) are bioresorbable polymers — chemically distinct from the general-purpose PLA filaments covered elsewhere in this catalog — extruded into filament, fiber or feedstock form specifically for 3D-printed medical devices designed to dissolve inside the body as natural bone or tissue regrows around them. The Industry splits into device-maker and feedstock-supplier layers: Singapore’s Osteopore 3D-prints polycaprolactone-tricalcium-phosphate (PCL-TCP) bone scaffolds via fused deposition modeling, with clinical case reports documenting use in critical-sized bone defects and a first custom implant delivered to a Hainan, China hospital in July 2026; Germany’s Evonik supplies its RESOMER and LACTEL bioabsorbable polymer portfolio — built over 30+ years — to device makers for orthopedic, dental and parenteral drug-delivery applications; the Netherlands’ Corbion supplies FDA-approved, GMP-grade PURASORB bioresorbable polymer grades used in additively manufactured bioresorbable stents and implant prototyping; and South Carolina’s Poly-Med vertically integrates polymer synthesis with extrusion into 3D-printing filaments, monofilament fibers and biomedical textiles, offering device makers a single CDMO partner from raw polymer to finished absorbable implant.

The key directions of bio-printing filaments (medical) are:

1. Bioresorbable PCL FDM bone scaffolds: Osteopore 3D-prints polycaprolactone-tricalcium-phosphate scaffolds via fused deposition modeling, documented in clinical case reports for critical-sized bone defect repair (including a calcaneal fracture case), and delivered its first custom orthopaedic implant to the Hainan branch of Shanghai Ruijin Hospital in July 2026.
2. Bioresorbable polymer feedstock for medical additive manufacturing: Evonik’s RESOMER and LACTEL portfolios supply bioabsorbable polymer excipients and biomaterials to medical technology companies across orthopedics, dental care and parenteral controlled-release drug delivery, drawing on over 30 years of biomaterials development.
3. FDA-approved bioresorbable implant polymer grades: Corbion’s PURASORB polymer grades (including PDLG copolymer formulations) are FDA-approved, GMP-grade materials increasingly used in additively manufactured bioresorbable stents and other implant prototypes, where polymer-grade selection is a device-performance design decision, not just a procurement one.
4. Vertically integrated bioresorbable filament-to-device manufacturing: Poly-Med extrudes its bioresorbable polymers directly into 3D-printing filaments, multifilament yarns, monofilament fibers and electrospun nanofibrous materials, and offers device makers vertically integrated CDMO services spanning absorbable orthopedic implants, craniomaxillofacial devices and biomedical textiles from a single polymer source.

Sectoral value chain

[bioresorbable polymer synthesis (PLA/PLGA/PCL grades)] ──> [extrusion into 3D-printing filament / fiber form]
                                                                          │
                                                          (FDM/FFF 3D printing into device or scaffold geometry)
                                                                          │
                                                                          ▼
[surgical implantation & clinical use] <─── [sterilization & regulatory clearance] <─── [device fabrication & finishing]

Value chain levels

Cross-cutting technologies of the sector:

• Bioresorbable PCL FDM bone scaffold (Bioresorbable PCL FDM Bone Scaffold): Osteopore’s fused-deposition-modeling process for polycaprolactone-tricalcium-phosphate scaffolds, clinically documented for critical-sized bone defect repair.
• Bioresorbable polymer feedstock for medical additive manufacturing (Bioresorbable Polymer Feedstock for Medical Additive Manufacturing): Evonik’s RESOMER and LACTEL bioabsorbable polymer portfolio, supplied as biomaterial feedstock across orthopedic, dental and drug-delivery device manufacturing.
• FDA-approved bioresorbable implant polymer grade (FDA-Approved Bioresorbable Implant Polymer Grade): Corbion’s PURASORB polymer grades, FDA-approved and GMP-grade, used in additively manufactured bioresorbable stents and implants.
• Vertically integrated bioresorbable filament-to-device manufacturing (Vertically Integrated Bioresorbable Filament-to-Device Manufacturing): Poly-Med’s single-source pipeline from bioresorbable polymer synthesis through filament/fiber extrusion to finished absorbable medical device and biomedical textile manufacturing.

02US

The US contributes the vertically integrated feedstock-to-device layer of this Industry: South Carolina’s Poly-Med extrudes its own bioresorbable polymers into 3D-printing filament and offers device makers a single CDMO partner from raw polymer to finished absorbable implant.

Poly-Med’s vertically integrated bioresorbable polymer-to-filament-to-device pipeline

• Poly-Med, Inc. (Anderson, South Carolina, USA): provides fully traceable, implant-grade bioresorbable polymers that can be processed by injection molding, extruded into multifilament yarns, monofilament fibers, films and 3D-printing filaments, or electrospun into nanofibrous materials; the company’s vertically integrated model — “from polymer to finished device” — extends to absorbable orthopedic and craniomaxillofacial implantable medical devices and absorbable biomedical textile manufacturing, positioning it as a CDMO partner rather than a filament-only supplier.
• US FDA bioresorbable implant clearance: bioresorbable orthopedic and craniomaxillofacial devices fabricated from Poly-Med’s filament and fiber feedstock are subject to FDA medical device clearance pathways specific to absorbable implants, distinct from the general consumer-product regulatory framing that applies to non-medical 3D-printing filament.

03CN

Singapore’s Osteopore delivered its first custom orthopaedic implant into China in July 2026 — to the Hainan branch of Shanghai Ruijin Hospital — marking an early cross-border expansion of bioresorbable 3D-printed bone scaffold technology into the Chinese market, though live sourcing this cycle did not confirm a China-headquartered company-specific bioresorbable medical filament or scaffold producer at a comparable scale, so no China-based producer is tabled this cycle.

Osteopore’s first China delivery and China’s medical device import pathway without a confirmed domestic originator

• Osteopore’s Hainan delivery: Osteopore Ltd (ASX: OSX), a Singapore company, delivered its first custom orthopaedic device to the Hainan branch of Shanghai Ruijin Hospital on 14 July 2026, an early signal of Chinese clinical demand for bioresorbable 3D-printed bone scaffold technology entering via import rather than domestic manufacturing.
• China’s NMPA medical device pathway without a confirmed domestic originator: China’s National Medical Products Administration governs the approval of imported and domestic bioresorbable implantable devices; live sourcing for this Industry found academic literature on 3D-printed bioceramic and biodegradable scaffolds originating from Chinese research institutions, but no confirmed China-headquartered commercial producer of bioresorbable medical 3D-printing filament or finished scaffold devices at the scale of Osteopore, Evonik, Corbion or Poly-Med; a domestic Chinese producer is a candidate for a future enrichment pass.

04EU

The EU supplies two of this Industry’s leading bioresorbable polymer feedstock suppliers: Germany’s Evonik and the Netherlands’ Corbion, both selling FDA-approved, GMP-grade bioresorbable polymer grades to medical device manufacturers worldwide.

Evonik’s RESOMER/LACTEL portfolio and Corbion’s PURASORB polymer grades

• Evonik (Germany): supplies the RESOMER® and LACTEL® bioabsorbable and bioresorbable polymer portfolios, marketed as degradable medical implant-grade 3D-printing material and as functional excipients for parenteral controlled-release drug delivery; Evonik’s biomaterials business spans orthopedic implants (temporary and permanent), dental implants and bone graft substitutes, and dental crown/bridge composite materials, drawing on more than 30 years of biomaterials development.
• Corbion (Gorinchem, South Holland, Netherlands): supplies the PURASORB® line of FDA-approved, GMP-grade bioresorbable polymers — including PDLG copolymer grades — for medical device formulations; Corbion frames polymer-grade selection as a device-performance design decision (mechanical behavior, in-tissue degradation rate, device survival) rather than a simple procurement choice, and its polymers are increasingly referenced in additive-manufacturing research on bioresorbable vascular stents.
• EU MDR & REACH: the EU’s Medical Device Regulation governs the conformity assessment and clinical-evidence requirements for bioresorbable implantable devices placed on the EU market, while REACH governs the chemical registration of the underlying bioresorbable polymer substances Evonik and Corbion place on the market.

05Leading companies and research institutes

06Tech stack and innovations

The bio-printing-filaments-medical stack spans the device-maker and feedstock-supplier layers of bioresorbable 3D printing — turning a synthesized polymer into filament, and filament into a clinically deployed device — unified by the requirement that the material resorb safely inside the body.

1. Bioresorbable PCL FDM bone scaffolds:
   • Osteopore’s polycaprolactone-tricalcium-phosphate scaffolds are fabricated by fused deposition modeling — the same extrusion-based printing family as general-purpose desktop 3D printing — but with a bioresorbable, tissue-compatible polymer-ceramic composite rather than a permanent plastic, directly enabling clinical use documented in peer-reviewed case reports for critical-sized bone defects.
   • The company’s first custom implant delivery into China (Hainan, July 2026) signals bioresorbable scaffold technology expanding via cross-border clinical adoption ahead of any confirmed domestic Chinese manufacturing competitor.
2. Bioresorbable polymer feedstock for medical additive manufacturing:
   • Evonik’s RESOMER and LACTEL portfolios decouple polymer synthesis expertise from device fabrication, letting medical technology companies formulate their own implants, dental devices or drug-delivery systems on a common, decades-proven bioabsorbable polymer base rather than developing bioresorbable chemistry in-house.
   • Spanning orthopedic, dental and parenteral drug-delivery applications from one polymer portfolio shows bioresorbable polymer feedstock functioning as horizontal infrastructure across multiple medical device categories, not a single-application material.
3. FDA-approved bioresorbable implant polymer grades:
   • Corbion’s framing of PURASORB grade selection as a design decision — not a procurement decision — reflects how a bioresorbable polymer’s degradation rate and mechanical profile are engineered into the specific clinical application, particularly for demanding uses like additively manufactured bioresorbable vascular stents.
   • FDA-approved, GMP-grade sourcing gives device makers a regulatory head start, since the base polymer’s safety and manufacturing-quality profile is already established before device-specific clinical evidence is generated.
4. Vertically integrated bioresorbable filament-to-device manufacturing:
   • Poly-Med’s single-source model — synthesizing the bioresorbable polymer and then extruding it directly into 3D-printing filament, fiber, yarn or electrospun nanofibrous form — removes the hand-off between polymer chemistry and filament production that otherwise separates feedstock suppliers like Evonik and Corbion from device-fabrication customers.
   • Extending vertical integration into finished absorbable orthopedic implants, craniomaxillofacial devices and biomedical textiles positions Poly-Med as a full CDMO rather than a materials supplier, a distinct business model from the feedstock-only approach of Evonik and Corbion.

07Value chains and production pipelines

Industrial pipeline of bio-printing filaments (medical) (from bioresorbable polymer synthesis to resorbed clinical implant)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Bioresorbable polymer  │ ───> │ 2. Filament / fiber       │
│    synthesis               │      │    extrusion                │
└───────────────────────────┘      └───────────────────────────┘
                                                  │
                                                  ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Sterilization &        │ <─── │ 3. Medical 3D printing /  │
│    regulatory clearance    │      │    device fabrication       │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Surgical implantation   │ ───> │ 6. Bioresorption &        │
│    & clinical use           │      │    tissue integration fate │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Bioresorbable polymer synthesis

Lactide, glycolide and caprolactone monomers feed Evonik’s RESOMER/LACTEL polymer synthesis in Germany, Corbion’s PURASORB polymer synthesis in the Netherlands, and Poly-Med’s own bioresorbable polymer synthesis in South Carolina, USA.

Stage 2: Filament / fiber extrusion

Poly-Med extrudes its bioresorbable polymer directly into 3D-printing filament, monofilament fiber, multifilament yarn or electrospun nanofibrous material; Evonik and Corbion supply their polymer grades as feedstock to device makers such as Osteopore, who perform their own extrusion and printing.

Stage 3: Medical 3D printing / device fabrication

Osteopore fabricates polycaprolactone-tricalcium-phosphate bone scaffolds via fused deposition modeling in Singapore; Corbion’s PURASORB grades are additively manufactured into bioresorbable vascular stents and implant prototypes in research and device-development settings; Poly-Med fabricates finished absorbable orthopedic, craniomaxillofacial and biomedical textile devices from its own filament and fiber feedstock.

Stage 4: Sterilization & regulatory clearance

Osteopore’s scaffolds and Poly-Med’s devices proceed through FDA and equivalent regulatory clearance pathways specific to bioresorbable implants; Evonik’s and Corbion’s polymer grades carry FDA-approved, GMP-grade status as feedstock; Osteopore’s Hainan delivery proceeds through China’s NMPA medical device import pathway.

Stage 5: Surgical implantation & clinical use

Osteopore’s scaffolds are surgically implanted for critical-sized bone defect repair, documented in case reports including a calcaneal fracture and now in clinical use at Shanghai Ruijin Hospital’s Hainan branch; Corbion’s PURASORB-based devices are researched and developed toward bioresorbable vascular stenting; Poly-Med’s devices are implanted for orthopedic hard-tissue anchoring, tendon-healing augmentation and craniomaxillofacial reconstruction.

Stage 6: Bioresorption & tissue integration fate

Osteopore’s PCL-TCP scaffolds, Evonik’s and Corbion’s polymer-based devices, and Poly-Med’s absorbable implants and textiles all gradually degrade in vivo over months to years as the patient’s own bone or tissue regenerates in their place, eliminating the need for a second surgery to remove permanent hardware.